Abstract
Introduction Increased vitamin D levels, as reflected by 25OHD measurements, has been proposed to protect against Covid-19 disease based on in-vitro, observational, and ecological studies. However, vitamin D levels are associated with many confounding variables and thus associations described to date may not be causal. Vitamin D MR studies have provided results that are concordant with large-scale vitamin D randomized trials. Here, we used two-sample MR to assess the effect of circulating 25OHD levels on Covid-19 susceptibility.
Methods and findings Genetic variants strongly associated with 25OHD levels in a 443,734-participant genome-wide association study (GWAS) were used as instrumental variables. GWASs of Covid-19 susceptibility and severity from the Covid-19 Host Genetics Initiative were used as outcomes. Cohorts from the Covid-19 Host Genetics Initiative GWAS included up to 14,134 individuals with Covid-19, and 1,284,876 with Covid-19, from 11 countries. Analyses were restricted to individuals of European descent when possible. Using inverse-weighted MR, genetically increased 25OHD levels by one standard deviation on the logarithmic scale had no clear association with Covid-19 susceptibility (OR = 0.97; 95% CI: 0.95, 1.10; P=0.613), hospitalization (OR = 1.11; 95% CI: 0.91, 1.35; P=0.299), and severe disease (OR = 0.93; 95% CI: 0.73, 1.17; P=0.531). We used an additional 6 meta-analytic methods, as well as sensitivity analysis after removal of variants at risk of horizontal pleiotropy, and obtained similar results. These results may be limited by weak instrument bias in some analyses. Further, our results do not apply to individuals with vitamin D deficiency.
Conclusion Our results do not support that patients be advised to take vitamin D supplementation to protect against Covid-19 outcomes. Further, other therapeutic or preventative avenues should be given higher priority for Covid-19 randomized controlled trials.
Author Summary
Why was this study done?
- The Covid-19 pandemic is the most important public health emergency in recent memory.
- Vitamin D levels have been associated with Covid-19 outcomes in multiple observational studies, though confounders are likely to bias these associations.
- By using genetic instruments which are not affected by such confounders, Mendelian randomization studies have steadily obtained results consistent with vitamin D supplementation randomized trials and may also be used in the context of Covid-19.
What did the researchers do and find?
- We used the genetic variants obtained from the largest cohort of Covid-19 cases and controls, and the largest study on genetic determinants of vitamin D levels.
- We used Mendelian randomization to combine these genetic variants to estimate the effect of increase vitamin D on Covid-19 outcomes, while controlling for confounders.
- In multiple analysis, our results consistently showed no evidence for an association between vitamin D levels and Covid-19 susceptibility, hospitalization, or severe disease.
What do these findings mean?
- Vitamin D is a highly confounded variables, and traditional observational studies are at high risk of biased estimates.
- We do not find evidence that vitamin D supplementation would improve Covid-19 outcomes.
- Given mendelian randomization’s past record with randomized controlled trial, other therapeutic and preventative avenues should be prioritized for Covid-19 randomized trials.
Competing Interest Statement
JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital. These agencies had no role in the design, implementation or interpretation of this study.
Funding Statement
The Richards research group is supported by the Canadian Institutes of Health Research (CIHR), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK and the Fonds de Recherche Quebec Sante (FRQS). GBL is supported by a joint scholarship from the FRQS and Quebec's Ministry of Health and Social Services. TN is supported by Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists and JSPS Overseas Challenge Program for Young Researchers. JBR is supported by a FRQS Clinical Research Scholarship. TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. These funding agencies had no role in the design, implementation or interpretation of this study. This research has been conducted using the UK Biobank Resource (project number: 27449).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Each cohort included in this study received their respective institutional research ethics board approval to enroll patients. All information used for this study are publicly available as deidentified GWAS summary statistics.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada and the Fonds de Recherche Québec Santé (FRQS). GBL is supported by a joint scholarship from the FRQS and Québec’s Ministry of Health and Social Services. TN is supported by Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists and JSPS Overseas Challenge Program for Young Researchers. JBR is supported by a FRQS Clinical Research Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London. These funding agencies had no role in the design, implementation or interpretation of this study.
Disclosures: JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital. These agencies had no role in the design, implementation or interpretation of this study.
Three major changes were made during the update. First, we used the most up to date Covid-19 Host Genetics Initiative (Covid-19 HGI) genome-wide association study summary statistics. Second, to alleviate potential selection and collider bias, we modified the outcome phenotypes to include population controls. Lastly, we performed additional mendelian randomization sensitivity analyses to check for the robustness of our results.
Data Availability
Covid-19 outcome GWAS summary statistics are freely available for download directly through the Covid-19 HGI website (https://www.covid19hg.org/results/). The October 20th data freeze summary statistics were used for our study.
